Please login to the form below

Not currently logged in
Email:
Password:

hyperkalaemia

This page shows the latest hyperkalaemia news and features for those working in and with pharma, biotech and healthcare.

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

NICE says no to AZ and Vifor’s rival hyperkalaemia drugs

Between 1% and 10% of hospital inpatients have hyperkalaemia. Many patients won’t display any symptoms, but some severe cases can lead to cardiac arrest. ... Hyperkalaemia is also seen in patients taking common medications for heart failure, such as

Latest news

More from news
Approximately 5 fully matching, plus 8 partially matching documents found.

Latest Intelligence

  • AstraZeneca’s focus on diagnosing and managing chronic kidney disease AstraZeneca’s focus on diagnosing and managing chronic kidney disease

    Hyperkalaemia (elevated levels of potassium in the blood) and anaemia are both common complications of CKD, associated with poorer cardiovascular outcomes and an increased risk of hospitalisation and death. ... For instance, we are exploring patient

  • Deal Watch July 2016 Deal Watch July 2016

    for the treatment of hyperkalaemia.

  • Deal Watch November 2015 Deal Watch November 2015

    Paying $90 per share (headline value $2.7bn) in acquiring ZS Pharma, AstraZeneca gains access to ZS-9, a possible best in class product for hyperkalaemia which is under FDA review. ... ZS Pharma. AstraZeneca. Acquisition - company. Lead product ZS-9,

  • Pharma deals during October 2013 Pharma deals during October 2013

    Examples of recent IPOS. Company. Product/technology. Target ($m). Relypsa. Patiromer for hyperkalaemia in chronic kidney disease (phase III).

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

Subscribe to our email news alerts

Featured jobs

PMHub

Add my company
Anthill Agency

Digital communications agency empowering clients through their digital transformation journey. Whether through training, delivering solutions or devising digital strategies, we...

Latest intelligence

Our Top 5 Pharma Picks From Cannes Lions
Here are five of Art's top five pharma and healthcare picks from Cannes Lions 2022....
The Evolving Role of the Sales Rep
The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
Measure your omnichannel maturity with our new tool
Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....